Customizing solutions for RNA-based therapeutics

A growing biotech company was researching early phase development of RNA-based therapies against cancer, a promising area of study that has shown potential to improve precision medicine with targeted therapy that weakens and slows the growth of harmful tumor cells. To best support their objectives, the client needed a contract research organization (CRO) partner with a global footprint and decades of oncology expertise to help them navigate their next-generation medicine from bench to market. As an emerging enterprise, flexibility and customizable solutions were critical for their program.